Related references
Note: Only part of the references are listed.Effects of monoclonal antibodies against amyloid-β on clinical and biomarker outcomes and adverse event risks: A systematic review and meta-analysis of phase III RCTs in Alzheimer's disease
Konstantinos Avgerinos et al.
AGEING RESEARCH REVIEWS (2021)
Tau-induced mitochondrial membrane perturbation is dependent upon cardiolipin
Angelique Camilleri et al.
BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES (2020)
LRRK2: Autophagy and Lysosomal Activity
Marta Madureira et al.
FRONTIERS IN NEUROSCIENCE (2020)
Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2020
Kevin McFarthing et al.
JOURNAL OF PARKINSONS DISEASE (2020)
Nucleic Acid-Based Therapeutics for Parkinson's Disease
Masayuki Nakamori et al.
NEUROTHERAPEUTICS (2019)
Depopulation of dense α-synuclein aggregates is associated with rescue of dopamine neuron dysfunction and death in a new Parkinson's disease model
Michal Wegrzynowici et al.
ACTA NEUROPATHOLOGICA (2019)
Late-stage Anle138b treatment ameliorates tau pathology and metabolic decline in a mouse model of human Alzheimer's disease tau
Matthias Brendel et al.
ALZHEIMERS RESEARCH & THERAPY (2019)
Multiple System Atrophy: Recent Developments and Future Perspectives
Wassilios G. Meissner et al.
MOVEMENT DISORDERS (2019)
A modulator of wild-type glucocerebrosidase improves pathogenic phenotypes in dopaminergic neuronal models of Parkinson's disease
Lena F. Burbulla et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
Anle138b modulates α-synuclein oligomerization and prevents motor decline and neurodegeneration in a mouse model of multiple system atrophy
Antonio Heras-Garvin et al.
MOVEMENT DISORDERS (2019)
Photophysics of diphenyl-pyrazole compounds in solutions and alpha-synuclein aggregates
Anne M. Reiner et al.
BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS (2018)
The Relevance of Iron in the Pathogenesis of Multiple System Atrophy: A Viewpoint
Christine Kaindlstorfer et al.
JOURNAL OF ALZHEIMERS DISEASE (2018)
Movement disorder society criteria for clinically established early Parkinson's disease
Daniela Berg et al.
MOVEMENT DISORDERS (2018)
The small molecule alpha-synuclein misfolding inhibitor, NPT200-11, produces multiple benefits in an animal model of Parkinson's disease
Diana L. Price et al.
SCIENTIFIC REPORTS (2018)
The diphenylpyrazole compound anle138b blocks A beta channels and rescues disease phenotypes in a mouse model for amyloid pathology
Ana Martinez Hernandez et al.
EMBO MOLECULAR MEDICINE (2018)
α-synuclein toxicity in neurodegeneration: mechanism and therapeutic strategies
Yvette C. Wong et al.
NATURE MEDICINE (2017)
Diagnosis and management of dementia with Lewy bodies Fourth consensus report of the DLB Consortium
Ian G. McKeith et al.
NEUROLOGY (2017)
Resolving the Atomistic Modes of Anle138b Inhibitory Action on Peptide Oligomer Formation
Dirk Matthes et al.
ACS CHEMICAL NEUROSCIENCE (2017)
Reducing tau aggregates with anle138b delays disease progression in a mouse model of tauopathies
Jens Wagner et al.
ACTA NEUROPATHOLOGICA (2015)
Anle138b and related compounds are aggregation specific fluorescence markers and reveal high affinity binding to ot-synuclein aggregates
Andreas A. Deeg et al.
BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS (2015)
The oligomer modulator anle138b inhibits disease progression in a Parkinson mouse model even with treatment started after disease onset
Johannes Levin et al.
ACTA NEUROPATHOLOGICA (2014)
Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson's disease
Jens Wagner et al.
ACTA NEUROPATHOLOGICA (2013)
Second consensus statement on the diagnosis of multiple system atrophy
S. Gilman et al.
NEUROLOGY (2008)
Share Paper
